US
Astellas’ Xospata becomes US-approved drug for FLT3-mutated acute myeloid leukaemia
November 29, 2018Sales and Marketing Astellas, FDA, US, Xospata, acute myeloid leukamia
Astellas has revealed that Xospata (gilteritinib) has been awarded FDA approval as a treatment for relapsed or refractory acute myeloid …
Opioid use disorder market to hit $4.8 billion by 2027, says GlobalData
November 26, 2018Sales and Marketing US, opioid crisis, opioids, pharma
New findings released by analytics firm GlobalData indicates that the market for opioid use disorder therapies is set to grow …
Top Ten most popular articles on Pharmafile.com this week!
November 23, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kymriah, Mundipharma, UK, US, brexit, pharma, politics, top 10
The appointment of GSK veteran Arnaud Breabout to the position of Senior Vice President and CFO of Mundipharma took the …
Pfizer’s Daurismo becomes first of its kind to secure FDA approval in acute myeloid leukaemia
November 22, 2018Research and Development, Sales and Marketing AML, Daurismo, FDA, Pfizer, US, leukaemia
Pfizer has revealed that the FDA has chosen to approve its Daurismo (glasdegib) for the treatment of newly-diagnosed acute myeloid …
Opioid dependency therapy price hiked 600% since 2014, Senate investigators find
November 20, 2018Manufacturing and Production, Sales and Marketing Evzio, Kaleo, Senate, US, naloxone, opioid crisis, opioid epidemic, opioids, pharma
Senate investigators have found that Virginia-based drugmaker Kaleo hiked the price of its opioid dependency therapy Evzio (naloxone) by as …
Novartis’ Promacta cleared by FDA for first-line use in severe aplastic anaemia
November 19, 2018Sales and Marketing FDA, Novartis, Promacta, Revolade, US, aplastic anaemia, pharma
Novartis has secured expanded approval from the FDA for Promacta (eltrombopag), allowing it to now be used in combination with …
MSD’s Keytruda chalks up FDA approval in liver cancer
November 12, 2018Sales and Marketing Cancer, FDA, US, hepatocellular carcinoma, keytruda, pharma
MSD’s blockbuster immunotherapy Keytruda has secured another FDA approval, this time for the treatment of hepatocellular carcinoma (HCC) in patients …
FDA approves BMS’ multiple myeloma combo after it doubles progression-free survival
November 7, 2018Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Empliciti, FDA, US, multiple myeloma, pharma
The FDA has seen fit to approve Bristol-Myers Squibb’s Empliciti (elotuzumab) intravenous injection in combination with pomalidomide and dexamethasone for …
FDA controversially approves potent opioid up to ten times stronger than fentanyl
November 6, 2018Sales and Marketing Dsuvia, FDA, US, fentanyl, opioid crisis, opioids, pharma
Despite voices of criticism, the FDA has opted to approve AcelRX’s Dsuvia (sufentanil), an opioid medication said to be five …
President Trump unveils new plans to bring US drug prices in line with the rest of the world
October 26, 2018Medical Communications, Sales and Marketing Drug pricing, Trump, US, pharma
Two weeks before the all-important midterm elections in the US, and after repeated strongly-worded promises, President Trump has unveiled an …
GSK to axe 99 positions at Memphis site
October 18, 2018Manufacturing and Production GSK, US, pharma
GlaxoSmithKline’s workforce on President’s Island in Memphis, US, is set to see the loss of 99 employees, as revealed in …
Trevena’s opioid injection fails to win over FDA committee
October 12, 2018Medical Communications, Sales and Marketing FDA, Trevena, US, oliceridine, opioid, opioid crisis, pharma
Trevena has seen its opioid injection oliceridine fail to win over an FDA advisory panel in the management of acute …
Novartis forge deal with Boston Pharmaceuticals in effort against AMR
October 3, 2018Research and Development AMR, Antibiotics, Boston Pharmaceuticals, Novartis, US
Swiss multinational Novartis have entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel …
Novo Nordisk cuts 650 roles around the world in R&D restructure
October 1, 2018Manufacturing and Production, Sales and Marketing China, Denmark, Novo Nordisk, UK, US, pharma
Novo Nordisk has announced a wave of jobs cuts as part of a global restructure of its $1 billion R&D …
The October 2018 issue of Pharmafocus is available to read online now!
September 27, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Hurricane Florence, NHS, Pharmafocus, US, biosimilars, market access, mental health, pharma
The October issue of Pharmafocus is available to read in full online now!Hurricane Florence lashed across North America’s Southeast coast …
Latest content
FibroFind appoints Lee Borthwick as CEO
